Immunovant, Inc.IMVTEarnings & Financial Report
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.
Revenue
$2.9M
Gross Profit
N/A
Operating Profit
$-62.8M
Net Profit
$-63.2M
Gross Margin
N/A
Operating Margin
-2134.5%
Net Margin
-2147.7%
YoY Growth
N/A
EPS
$-0.49
Immunovant, Inc. Q3 FY2023 Financial Summary
Immunovant, Inc. reported revenue of $2.9M for Q3 FY2023, with a net profit of $-63.2M (down 52.8% YoY) (-2147.7% margin).
Key Financial Metrics
| Total Revenue | $2.9M |
|---|---|
| Net Profit | $-63.2M |
| Gross Margin | N/A |
| Operating Margin | -2134.5% |
| Report Period | Q3 FY2023 |
Immunovant, Inc. Annual Revenue by Year
Immunovant, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $24.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $24.9M |
| 2023 | $7.6M |
Immunovant, Inc. Quarterly Revenue & Net Profit History
Immunovant, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $8.4M | +140.7% | $-75.3M | -899.0% |
| Q3 FY2024 | $8.9M | +203.4% | $-51.4M | -575.6% |
| Q2 FY2024 | $3.6M | +209.5% | $-58.7M | -1642.3% |
| Q1 FY2024 | $4.1M | — | $-73.9M | -1818.9% |
| Q4 FY2023 | $3.5M | — | $-59.4M | -1707.8% |
| Q3 FY2023 | $2.9M | — | $-63.2M | -2147.7% |
| Q2 FY2023 | $1.2M | — | $-47.9M | -4153.2% |
| Q1 FY2023 | $0 | — | $-40.4M | N/A |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.2M | $2.9M | $3.5M | $4.1M | $3.6M | $8.9M | $8.4M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 209.5% | 203.4% | 140.7% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $458.7M | $428.1M | $456.2M | $405.8M | $351.2M | $292.1M | $711.4M | $666.4M |
| Liabilities | $22.2M | $32.4M | $41.6M | $43.3M | $51.4M | $40.3M | $32.1M | $48.6M |
| Equity | $436.5M | $395.7M | $414.7M | $362.5M | $299.9M | $251.8M | $679.3M | $617.8M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-65.8M | $-20.2M | $-46.4M | $-55.8M | $-47.4M | $-60.1M | $-47.1M | $-59.7M |